Topiramate vs. Amitriptyline in prophylactic treatment of migraine: A controlled clinical trial

Revista Mexicana de Neurociencia

Volumn 11, Issue 5, 2010, Pages 338-342

  Rodríguez Leyva, Ildefonso ^a   Sánchez Aguilar, M C Jesús Martín ^b   Hernández Sierra, Juan Francisco ^b   Mandeville, Peter B ^b   Rodríguez Leyva, Ma Del Rocío ^a   Shiguetomi Medina, Juan Manuel ^a   Tapia Pérez, Jorge Humberto ^c  

^a HOSPITAL CENTRAL DR IGNACIO MORONES PRIETO   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Amitriptyline; Migraine; Prophylaxis; Topiramate

Indexed keywords

AMITRIPTYLINE; KETOROLAC; TOPIRAMATE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE;

EID: 79953224826     PISSN: 16655044     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Headache Classification Committee of the International Headache Society. Classification and Diagnostic Criteria for Headache Disorders, Cranial Neuralgia, and Facial Pain. Cephalalgia 1988; 8(7): 1-96.
2. The International Classification of Headache Disorders. 2nd Ed. Headache Classification Subcommittee of the International Headache Society. Cephalalgia 2004; 24(Suppl. 1): 8-152.
3. Silberstein S, Lipton R, Dalessio D. Overview, Diagnosis, and Classification of Headache in Wolff's Headache and Other Head Pain. 7th Ed. Oxford University Press; 2001: 22-58.
4. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22(7): 491-512. (Pubitemid 36609343)
5. McCrory DC, Matchar DB, Rosenberg JH, Silberstein SD. Evidence-based guidelines for migraine headache: overview of program description and methodology. Neurology. [Serial online] URL: http://www.neurology.org Accessed April 25, 2000.
6. Matchar DB, Young WB, Rosenberg JA, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Available from the American Academy of Neurology. Accessed April 25, 2000.
7. Topiramate (Topamax) for prevention of migraine. Med Lett Drugs Ther 2005; 47(1201): 9-10.
8. McCrory DC, Matchar DB, Rosenberg JH, Silberstein SD. Evidence-based guidelines for migraine headache: overview of program description and methodology. Neurology. [Serial online] URL: http://www.neurology.org Accessed April 25, 2000.
9. Matchar DB, Young WB, Rosenberg JA, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Available from the American Academy of Neurology. Accessed April 25, 2000.
10. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology. [Serial online] URL: http://www.neurology.org Accessed April 25, 2000.
11. Guidelines for controlled trials of drugs in migraine. The IHS Member's Handbook 1997/1998. 1sr Ed. 111-133.
12. Stewart WF, Lipton RB, Kolodner K. Migraine Disability Assessment (MIDAS) Score: Relation to Headache Frequency, Pain Intensity, and Headache Symptoms. Headache 2003; 43(3): 258-65.
13. Chatterton ML, Lofland JH, Schechter A, Curtice WS, Hu XH, Lenow J, Smullens SN, Nash DB, Silberstein SD. Reliability and validity of the migraine therapy assessment questionnaire. Headache 2002; 42(10): 1006-15. (Pubitemid 35470708)
14. Fragoso VD. MIDAS (Migraine Disability Assessment): a valuable tool for work-site identification of migraine in workers in Brazil. Sao Paulo Med J 2002; 120(4): 118-21.
15. Stewart W, Lipton R. Need for care and perceptions of MIDAS among headache sufferers study. CNS Drugs 2002; 16(Suppl. 1): 5-11.
16. Damico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, Leone M, Puca FM, Bussone G. The Migraine Disability Assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 2001; 21(10): 947-52. (Pubitemid 34626030)
17. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001; 41(9): 854-61. (Pubitemid 33043148)
18. Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology 2001; 56(6 Suppl. 1): 35-42.
19. Edmeads J, Lainez JM, Brandes JL, Schoenen J, Freitag F. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 2001; 56(6 Suppl. 1): S29-34.
20. Santos Zambrano JA, Rodríguez Leyva I, Salinas Estebané R, Fernández Alvarado B, Nuñez Orozco L. Estudio multicéntrico abierto para evaluar la eficacia y seguridad del tratamiento profiláctico de migraña con topiramato. Rev Mex Neuroci 2005; 6(1): 38-41.
21. Browne RH. On the use of a pilot simple for sample size determination. Stat Med 1995; 14: 1933-40.
22. R: Copyright 2004. The R Foundation for Statistical Computing Version 2.0.1 (2004-11-15). ISBN 3-900051-07-0.
23. Stang PE, Von Korff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 1994; 34(3): 138-42. (Pubitemid 24129303)
24. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol 2005; 20(3): 243-9. (Pubitemid 40569173)
25. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15(1): 45-68.
26. Goldberg LD. The cost of migraine and its treatment. Am J Manag Care 2005; 11(2): 62-7.
27. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45(Suppl. 1): S3-S13. (Pubitemid 40532985)
28. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000; 41(Suppl. 1): 61-5.
29. Kirov G, Tredget J. Add-on Topiramate reduces weight in overweight patients with affective disorders: a clinical case series. BMC Psychiatry 2005; 5(1): 19.
30. Krymchantowski A, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Med Gen Med 2004; 6(3): 48.
31. Sahli Ch, Bryois Ch. Psychotropics and weight gain. Schweiz Rundsch Med Prax 2004; 93(35): 1393-401.
32. Van Ameringen M, Mancini C, Pipe B, Campbell M, Oakman J. Topiramate treatment for SSRI-induced weight gain in anxiety disorders. J Clin Psychiatry 2002; 63(11): 981-4. (Pubitemid 35388055)
33. Brown JS, Papadopoulos G, Neumann PJ, Friedman M, Miller JD, Menzin J. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment. Headache 2005; 45(8): 1012-22.
34. Instituto Mexicano del Seguro Social (IMSS). Comparativo de Precios de Adquisición de Medicamentos. March, 2005.
35. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251(8): 943-50. (Pubitemid 39119312)
36. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997; 17(2): 73-80. (Pubitemid 27167496)